CDXS CODEXIS, INC.

Nasdaq codexis.com


$ 1.60 $ -0.11 (-5.35 %)    

Thursday, 06-Nov-2025 17:01:48 EST
QQQ $ 612.95 nm (nm)
DIA $ 469.80 $ -3.83 (-0.81 %)
SPY $ 671.67 nm (nm)
TLT $ 89.76 nm (nm)
GLD $ 365.71 nm (nm)
$ 2.035
$ 2.15
$ 1.57 x 3
$ 1.70 x 200
$ 2.03 - $ 2.16
$ 1.90 - $ 6.08
658,716
na
173.77M
$ 2.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-03-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-27-2023 12-31-2022 10-K
13 11-04-2022 09-30-2022 10-Q
14 08-05-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-08-2020 03-31-2020 10-Q
24 02-28-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-01-2019 12-31-2018 10-K
29 11-09-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-15-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-09-2017 12-31-2016 10-K
37 11-08-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-08-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 in-october-codexis-announces-signing-of-378m-supply-assurance-agreement-with-merck-reduced-around-24-of-its-workforce

As of September 30, 2025, the Company had $58.7 million in cash, cash equivalents and short-term investments.In November 2025, ...

 codexis-and-nitto-denko-avecia-sign-agreement-to-evaluate--codexis-eco-synthesis-manufacturing-platform

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, ...

 codexis-q2-eps-016-beats-019-estimate-sales-1533m-beat-1411m-estimate

Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15...

 codexis-presents-data-at-tides-usa-showcasing-proprietary-eco-synthesis-platforms-ability-to-support-sirna-manufacturing-by-reducing-purification-costs-improving-process-performance-and-demonstrating-potential-to-control-stereochemistry

Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis ...

 codexis-affirms-fy2025-sales-guidance-of-6400m-6800m-vs-6567m-est

Codexis (NASDAQ:CDXS) affirms FY2025 sales outlook from $64.00 million-$68.00 million to $64.00 million-$68.00 million vs $65.6...

 codexis-q1-eps-025-misses-023-estimate-sales-754m-miss-966m-estimate

Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by ...

 preview-codexiss-earnings
Preview: Codexis's Earnings
05/13/2025 21:03:14

 codexis-secures-first-revenue-deal-for-eco-synthesis-marks-milestone-in-enzymatic-sirna-manufacturing

Represents first project to enter the ECO Synthesis™ Innovation LabCore enzymes for ECO Synthesis™ technology have transitioned...

 codexis-sees-fy2025-sales-64000m-68000m-vs-6661m-est

Codexis (NASDAQ:CDXS) sees FY2025 sales of $64.000 million-$68.000 million vs $66.61 million analyst estimate.

 codexis-q4-eps-013-misses-004-estimate-sales-2146m-miss-2741m-estimate

Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.04) by ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION